Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of DEC205mAb-NY-ESO-1 Fusion Protein (CDX-1401) Given With Adjuvant PolyICLC in Conjunction With 5-Aza-2'Deoxycytidine (Decitabine) in Patients With MDS or Low Blast Count AML

Next Previous
X
Search
Trial Profile

A Phase 1 Study of DEC205mAb-NY-ESO-1 Fusion Protein (CDX-1401) Given With Adjuvant PolyICLC in Conjunction With 5-Aza-2'Deoxycytidine (Decitabine) in Patients With MDS or Low Blast Count AML

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 26 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rasdegafusp-alfa (Primary) ; Rasdegafusp-alfa (Primary) ; Decitabine; Poly ICLC
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions

    • Most Recent Events

    • 20 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 06 Dec 2016 Updated results after complete study accrual, presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 05 Dec 2016 Results will be presented at the American Society of Hematology (ASH) Annual Meeting, as per a Celldex media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top